Shorter TB regimens could simplify treatment
NCT ID NCT07668479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether shorter, rifapentine-based treatments for tuberculosis and latent TB are safe and effective in real-world settings in Kazakhstan. It will follow 350 adults, including those with HIV, comparing a 4-month regimen to the standard 6-month one for active TB, and a 1-month regimen for latent TB. The goal is to see if these shorter options can improve cure rates and reduce side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rifapentine (combined with isoniazid, moxifloxacin, pyrazinamide, or ethambutol)
What this could lead to
If successful, this could show that shorter TB treatments work as well as standard ones, making it easier for patients to complete therapy and reducing the spread of TB.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects from the shorter regimens could still occur, and findings may not apply outside Kazakhstan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••